Leap Therapeutics, Inc. (NASDAQ:LPTX)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $5.27 and last traded at $5.27, with a volume of 31,944 shares. The stock had previously closed at $5.69.

Separately, Zacks Investment Research upgraded shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th.

The stock’s market capitalization is $50.12 million. The company has a 50-day moving average of $5.88 and a 200-day moving average of $5.88.

Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Friday, August 11th. The company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.03). Equities research analysts forecast that Leap Therapeutics, Inc. will post ($3.16) earnings per share for the current year.

An institutional investor recently bought a new position in Leap Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned approximately 0.48% of Leap Therapeutics as of its most recent SEC filing. 0.81% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/28/leap-therapeutics-inc-lptx-sets-new-12-month-low-at-5-27.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Receive News & Stock Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related stocks with our FREE daily email newsletter.